Reviews/Chronic Pain Pharmacotherapy/Pregabalin reduces pain scores in diabetic peripheral neuropathy
Gab · CPP-GAB-01 · v2
Several separate, well-designed trials gave people with diabetic nerve pain either pregabalin or a dummy pill without either side knowing which, then measured pain using patients' own daily pain diaries. In the 300 to 600 mg per day range, pregabalin lowered pain more than the dummy pill, and this was seen again in analyses that pooled many trials and in studies run in the United States, Japan and Iran [1][2][6][9][3][16][18]. The amount of pain relief was real but small, and lower doses often did no better than the dummy pill [4][9][16]. One trial that used pregabalin only as a yardstick found its benefit faded during the study [26]. The panel concluded the drug genuinely reduces pain, while noting the effect is modest and depends on dose.
Multiple independent double-blind, placebo-controlled trials in diabetic peripheral neuropathy measured pain itself as the primary endpoint and found pregabalin significantly better than placebo at 300 to 600 mg/day: [1] (N=146, P<0.0001), [2] (N=338, p=0.0001), [4] (600 mg significant), [6] (mean difference -1.28, p<.001) and [9] (N=317, Japanese patients, P<0.05). Pooled analyses of primary data reproduce the effect [3] (seven trials) and [16] (DPN cohort N=3,056, placebo-adjusted -0.73). An independent randomized trial in Iran also showed pain reduction with pregabalin [18]. Because pain score is the claimed quantity and the measured endpoint, there is no surrogate gap. The effect is modest, for example placebo-adjusted differences of -0.63 and -0.74 on an 11-point scale in [9]. The contested point: The division is over magnitude and dose, not direction. Lower doses of 150 to 300 mg/day repeatedly failed to separate from placebo [4], the absolute effect on raw pain scales is small [9][16], and one trial using pregabalin as a positive control saw only transient benefit [26].
All 40 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Chronic Pain Pharmacotherapy, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
In [26], a placebo-controlled trial using pregabalin as the positive control, pregabalin (150 mg BID) produced only a transient improvement in pain that did not persist throughout the study — the corpus itself contains a case where the effect was not robust.
Dose dependence: [4] reports that pregabalin 150 and 300 mg/day did not separate from placebo in that trial; efficacy is concentrated at 600 mg, so the unqualified claim overstates low-dose benefit.
Where it remains uncertain. Benefit concentrates at higher doses while 150 to 300 mg/day often did not separate from placebo [4], absolute reductions are small [9][16], and one positive-control arm showed only transient improvement [26].
Aleatory
An atypically large placebo response in one country representing 42% of patients obscured lower-dose separation in [4].
Epistemic
The pivotal placebo-controlled trials ran only 5 to 14 weeks [1][2][6][9], leaving durability of pain reduction beyond a few months untested in this corpus.
Inferential
Active-comparator and combination designs [7][20][24] have no placebo arm, so inferring an absolute pregabalin effect from them is unsupported.
The load-bearing papers from a corpus of 40, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Pivotal placebo-controlled DPN RCT (300 mg) with pain score as primary endpoint.
“Pregabalin produced significant improvements versus placebo for mean pain scores (P < 0.0001)”
Panel auditInternal validity: high · scope of inference: Patients with 1- to 5-year history of painful DPN, single 300 mg/day dose, 8 weeks.Key limitations: single dose arm · short duration · modest sample
Independent dose-ranging placebo-controlled DPN RCT confirming pain reduction.
“Patients in the 300- and 600-mg/day pregabalin groups showed improvements in endpoint mean pain score (primary efficacy measure) vs placebo (p = 0.0001)”
Panel auditInternal validity: high · scope of inference: DPN patients, 1- to 5-year history, 5 weeks; 75 mg did not separate from placebo.Key limitations: 75 mg dose ineffective · short 5-week duration
Pooled primary-data analysis across seven trials, dose-related effect.
“Pooled analysis showed that pregabalin significantly reduced pain and pain-related sleep interference associated with DPN (150, 300, and 600 mg/day administered TID vs. placebo, all P < or = 0.007)”
Panel auditInternal validity: medium · scope of inference: DPN patients across 7 trials, 5–13 week durations.Key limitations: heterogeneous dosing schedules · short durations · pooled design
The abstract reports pregabalin response rates against lidocaine, not against placebo, so it cannot establish reduction versus no treatment.
Panel auditInternal validity: low · scope of inference: Localized neuropathic pain (PHN and DPN), 4-week comparative phase.Key limitations: open-label · no placebo arm · non-inferiority vs active drug
4 of 40 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
Consistent, directly-measured, placebo-controlled pain-score reductions across many independent DPN RCTs establish the claim, with confidence held just below ceiling by modest effect size and dose dependence.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Long-term durability of pain relief. All placebo-controlled DPN trials in the corpus are short (5 to 14 weeks) [1][2][6][9], so sustained benefit in a chronic condition is unestablished. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A long-duration (>=6 month) double-blind placebo-controlled DPN trial with the mean pain score as primary endpoint.
Open question: Does pregabalin's pain-score reduction in DPN persist beyond three to four months? Why it is still open: The placebo-controlled trials establishing the effect are 5 to 14 weeks long [1][2][6][9], with no longer placebo-controlled follow-up in the corpus.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19